DBVTHIGH SIGNALFINANCIAL10-K

DBVT underwent a massive capital raise that more than doubled outstanding shares while dramatically strengthening its cash position to $194.2M.

The company raised substantial capital through what appears to be a significant equity offering, increasing shares outstanding from 137M to 296M (116% dilution). This provides crucial runway for operations and R&D, but at the cost of major shareholder dilution.

Comparing 2026-03-26 vs 2025-04-11View on EDGAR →
FINANCIAL ANALYSIS

DBVT experienced a transformational financial period with cash increasing nearly 500% to $194.2M and stockholders' equity surging over 500% to $168.8M, clearly indicating a major capital raise. While R&D expenses grew 31% to $116.7M reflecting continued investment in their pipeline, the company significantly strengthened its balance sheet and reduced debt by 60%. The massive improvement in liquidity provides substantial operational runway, though the doubling of share count represents significant dilution to existing shareholders.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+516.2%
$27.4M$168.8M

Equity base grew 516.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+498.2%
$32.5M$194.2M

Cash position surged 498.2% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+379.7%
$44.4M$212.9M

Current assets grew 379.7% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+256%
$65.7M$233.7M

Asset base grew 256% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+86.4%
$31.1M$58.0M

Current liabilities surged 86.4% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-77.2%
$2.3M$532K

Capex reduced 77.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
+69.7%
$38.3M$64.9M

Liabilities grew 69.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Debt
Balance Sheet
-59.7%
$1.3M$510K

Debt reduced 59.7% — deleveraging strengthens balance sheet and reduces financial risk.

Revenue
P&L
+35.8%
$4.2M$5.6M

Strong top-line growth of 35.8% — accelerating demand or successful expansion into new markets.

R&D Expense
P&L
+30.6%
$89.3M$116.7M

R&D investment increased 30.6% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-04-11
ADDED
As of March 25, 2026, the registrant had 296,042,447 ordinary shares, nominal value 0.10 per share, outstanding.
F - 3 Currently, we do not have commercial-ready marketing and sales infrastructure.
If we are not able to comply with the applicable continued listing requirements or standards of the Nasdaq Capital Market ( Nasdaq ) our ADSs could be delisted.
We believe Viaskin technology may offer convenient, non-invasive immunotherapy to patients.
Our most advanced product candidate is Viaskin Peanut Patch, which has been evaluated as a potential therapy for children with peanut allergy in twelve completed clinical trials, including five Phase 2 trials and five completed Phase 3 trials.
+7 more — sign up free →
REMOVED
As of April 10, 2025, the registrant had 136,948,872 ordinary shares, nominal value 0.10 per share, outstanding.
Currently, we do not have commercial-ready marketing and sales infrastructure.
If we are not able to comply with the applicable continued listing requirements or standards of the Nasdaq Capital Market, or Nasdaq, our ADSs could be delisted.
We believe Viaskin may offer convenient, , non-invasive immunotherapy to patients.
Our most advanced product candidate is Viaskin Peanut, which has been evaluated as a potential therapy for children with peanut allergy in eleven clinical trials, including four Phase 2 trials and four completed Phase 3 trials.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →